Molecular characteristics of Neisseria meningitidis carriage strains in university students in Lithuania.


Journal

BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981

Informations de publication

Date de publication:
17 Nov 2023
Historique:
received: 01 05 2023
accepted: 06 11 2023
medline: 27 11 2023
pubmed: 18 11 2023
entrez: 18 11 2023
Statut: epublish

Résumé

Neisseria meningitidis can be carried asymptomatically in the human oropharynx without causing symptoms. Meningococcal carriage is relevant to the epidemiology of invasive meningococcal disease (IMD). No carriage studies have been performed among the general population in Lithuania, whereas the incidence of IMD in Lithuania was among the highest in European countries from 2009 to 2019. We analyzed a total of 401 oropharyngeal samples collected from university students from December 2021 to February 2023 for N. meningitidis carriage using direct swab PCR assays and culture. The overall carriage prevalence based on both or either swab PCR or culture was 4.99%. PCR-based assays were used to characterize 15 carriage isolates, including detection of genogroup, multilocus sequence typing profile, and typing of antigens PorA and FetA. The most common carriage isolates were capsule null locus (cnl), accounting for 46.7%, followed by genogroups B (26.7%) and Y (13.3%). We also performed a molecular characterization of invasive N. meningitidis isolates collected during the COVID-19 pandemic and post-pandemic period to understand better the meningococcal carriage in the context of prevailing invasive strains. Despite the substantial decrease in the incidence of IMD during the 2020-2022 period, clonal complex 32 (CC32) of serogroup B continued to be the most prevalent IMD-causing CC in Lithuania. However, CC32 was not detected among carriage isolates. The most common CCs were CC269, CC198, and CC1136. The antigen peptide variants found in most carried isolates were classified as 'insufficient data' according to the MenDeVAR Index to evaluate the potential coverage by the 4CMenB vaccine. Nearly half of the isolates were potentially covered by the Men-Fhbp vaccine. Resistance to ciprofloxacin was detected only for one cnl isolate. All isolates were susceptible to penicillin and ceftriaxone. Our analysis identified frequent partying (≥ 4 times/month) as a risk factor for meningococcal carriage, whereas smoking, living in a dormitory, and previous COVID-19 illness were not associated with the carriage. Our study revealed a low prevalence of meningococcal carriage among university students in Lithuania. The carriage isolates showed genetic diversity, although almost half of them were identified as having a null capsule locus.

Sections du résumé

BACKGROUND BACKGROUND
Neisseria meningitidis can be carried asymptomatically in the human oropharynx without causing symptoms. Meningococcal carriage is relevant to the epidemiology of invasive meningococcal disease (IMD). No carriage studies have been performed among the general population in Lithuania, whereas the incidence of IMD in Lithuania was among the highest in European countries from 2009 to 2019.
RESULTS RESULTS
We analyzed a total of 401 oropharyngeal samples collected from university students from December 2021 to February 2023 for N. meningitidis carriage using direct swab PCR assays and culture. The overall carriage prevalence based on both or either swab PCR or culture was 4.99%. PCR-based assays were used to characterize 15 carriage isolates, including detection of genogroup, multilocus sequence typing profile, and typing of antigens PorA and FetA. The most common carriage isolates were capsule null locus (cnl), accounting for 46.7%, followed by genogroups B (26.7%) and Y (13.3%). We also performed a molecular characterization of invasive N. meningitidis isolates collected during the COVID-19 pandemic and post-pandemic period to understand better the meningococcal carriage in the context of prevailing invasive strains. Despite the substantial decrease in the incidence of IMD during the 2020-2022 period, clonal complex 32 (CC32) of serogroup B continued to be the most prevalent IMD-causing CC in Lithuania. However, CC32 was not detected among carriage isolates. The most common CCs were CC269, CC198, and CC1136. The antigen peptide variants found in most carried isolates were classified as 'insufficient data' according to the MenDeVAR Index to evaluate the potential coverage by the 4CMenB vaccine. Nearly half of the isolates were potentially covered by the Men-Fhbp vaccine. Resistance to ciprofloxacin was detected only for one cnl isolate. All isolates were susceptible to penicillin and ceftriaxone. Our analysis identified frequent partying (≥ 4 times/month) as a risk factor for meningococcal carriage, whereas smoking, living in a dormitory, and previous COVID-19 illness were not associated with the carriage.
CONCLUSIONS CONCLUSIONS
Our study revealed a low prevalence of meningococcal carriage among university students in Lithuania. The carriage isolates showed genetic diversity, although almost half of them were identified as having a null capsule locus.

Identifiants

pubmed: 37978423
doi: 10.1186/s12866-023-03111-5
pii: 10.1186/s12866-023-03111-5
pmc: PMC10655475
doi:

Substances chimiques

Meningococcal Vaccines 0
Bacterial Vaccines 0
Antigens, Bacterial 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

352

Subventions

Organisme : The European Regional Development Fund under a grant agreement with the Research Council of Lithuania
ID : No 01.2.2-LMT-K-718-03-0036
Organisme : The European Regional Development Fund under a grant agreement with the Research Council of Lithuania
ID : No 01.2.2-LMT-K-718-03-0036
Organisme : The European Regional Development Fund under a grant agreement with the Research Council of Lithuania
ID : No 01.2.2-LMT-K-718-03-0036
Organisme : The European Regional Development Fund under a grant agreement with the Research Council of Lithuania
ID : No 01.2.2-LMT-K-718-03-0036
Organisme : The European Regional Development Fund under a grant agreement with the Research Council of Lithuania
ID : No 01.2.2-LMT-K-718-03-0036
Organisme : The European Regional Development Fund under a grant agreement with the Research Council of Lithuania
ID : No 01.2.2-LMT-K-718-03-0036
Organisme : The European Regional Development Fund under a grant agreement with the Research Council of Lithuania
ID : No 01.2.2-LMT-K-718-03-0036
Organisme : The European Regional Development Fund under a grant agreement with the Research Council of Lithuania
ID : No 01.2.2-LMT-K-718-03-0036
Organisme : The European Regional Development Fund under a grant agreement with the Research Council of Lithuania
ID : No 01.2.2-LMT-K-718-03-0036
Organisme : The European Regional Development Fund under a grant agreement with the Research Council of Lithuania
ID : No 01.2.2-LMT-K-718-03-0036

Informations de copyright

© 2023. The Author(s).

Références

Clin Microbiol Infect. 2022 Dec;28(12):1649.e1-1649.e8
pubmed: 35840033
Expert Rev Vaccines. 2022 Jan;21(1):103-114
pubmed: 34747302
Microbiology (Reading). 2002 Jun;148(Pt 6):1813-1819
pubmed: 12055301
Epidemiol Infect. 2023 Mar 06;151:e57
pubmed: 37052295
Lancet Infect Dis. 2021 May;21(5):677-687
pubmed: 33482143
Clin Infect Dis. 2020 Apr 10;70(8):1761-1763
pubmed: 31420664
Microorganisms. 2022 Apr 26;10(5):
pubmed: 35630352
Epidemiol Infect. 2023 Feb 13;151:e25
pubmed: 36775828
PLoS One. 2015 Jul 06;10(7):e0132140
pubmed: 26147212
FEMS Microbiol Rev. 2007 Jan;31(1):52-63
pubmed: 17233635
mBio. 2021 May 18;12(3):
pubmed: 34006659
Emerg Infect Dis. 2006 Jun;12(6):950-7
pubmed: 16707051
Clin Microbiol Infect. 2017 Aug;23(8):573.e1-573.e7
pubmed: 28192234
Open Forum Infect Dis. 2022 Sep 19;9(10):ofac482
pubmed: 36225741
J Clin Microbiol. 2009 Nov;47(11):3577-85
pubmed: 19759227
Epidemiol Infect. 2020 Mar 31;148:e80
pubmed: 32228726
Front Cell Infect Microbiol. 2023 Feb 15;13:1136211
pubmed: 36875527
Int J Med Microbiol. 2019 May - Jun;309(3-4):182-188
pubmed: 30878541
mSphere. 2018 Dec 5;3(6):
pubmed: 30518675
Clin Vaccine Immunol. 2010 Jun;17(6):919-29
pubmed: 20375242
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 33055180
Crit Rev Microbiol. 2016 Sep;42(5):759-72
pubmed: 26089023
Expert Rev Anti Infect Ther. 2017 Jul;15(7):689-701
pubmed: 28524748
J Infect Dis. 2009 Aug 1;200(3):379-89
pubmed: 19534597
Hum Vaccin Immunother. 2018 May 4;14(5):1118-1130
pubmed: 29565712
Clin Vaccine Immunol. 2011 Jun;18(6):1002-14
pubmed: 21508163
J Comput Biol. 2012 May;19(5):455-77
pubmed: 22506599
Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):271-6
pubmed: 8990198
Lancet Infect Dis. 2010 Dec;10(12):853-61
pubmed: 21075057
Wellcome Open Res. 2018 Sep 24;3:124
pubmed: 30345391
PLoS One. 2014 Feb 24;9(2):e89921
pubmed: 24587125
Emerg Infect Dis. 2013 Apr;19(4):566-73
pubmed: 23628376
Epidemiol Infect. 2003 Feb;130(1):59-70
pubmed: 12613746

Auteurs

Inga Ivaškevičienė (I)

Clinic of Children's Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Pediatric Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.

Justina Silickaitė (J)

Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.

Asta Mačionienė (A)

Center of Laboratory Medicine, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.

Rimvydas Ivaškevičius (R)

Clinic of Children's Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Pediatric Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.

Aistė Bulavaitė (A)

Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.

Vilmantas Gėgžna (V)

Institute of Biosciences, Life Sciences Center, Vilnius University, Vilnius, Lithuania.

Silvija Kiverytė (S)

Center of Laboratory Medicine, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Department of Physiology, Biochemistry, Microbiology and Laboratory Medicine Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Božena Paškevič (B)

Clinic of Children's Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Pediatric Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.

Aurelija Žvirblienė (A)

Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.

Milda Plečkaitytė (M)

Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania. milda.pleckaityte@bti.vu.lt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH